Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record.

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet

Schwartz, J. I., Vandormael, K., Malice, M. P., Kalyani, R. N., Lasseter, K. C., Holmes, G. B., Gertz, B. J., Gottesdiener, K. M., Laurenzi, M., Redfern, K.‐J., Brune, K.·2002·Clinical Pharmacology & Therapeutics

Abstract

Background: This study compared directly the renal effects of two selective cyclooxygenase (COX)‐2 inhibitors (rofecoxib and celecoxib) with naproxen (dual COX‐1/COX‐2 inhibitor) and placebo in healthy elderly subjects on a sodium‐replete diet. Methods: A total of 67 elderly subjects stabilized in the clinic for weight andurinary sodium on a controlled 200‐mEq sodium diet were randomized in a double‐blind fashion to receive rofecoxib, 25 mg daily (n = 17); celecoxib, 200 mg twice daily (n = 17); naproxen, 500 mg twice daily (n = 17); or matching placebo (n = 16) for 28 days. Subjects were sequestered in the clinic for the first 14 treatment days on the controlled diet. Results: Daily urinary sodium excretion during the first 72 hours of treatment (primary endpoint) significantly decreased in rofecoxib, celecoxib, and naproxen groups compared with baseline (P ≤ .05). Rofecoxib and celecoxib decreases in urinarysodium excretion rates that were comparable with each other, on the basis of predefined boundaries (−39.5 versus −27.1 mEq/d, respectively) and to naproxen (−40.6, mEq/d). Rofecoxib, celecoxib, and naproxen increased mean systolic blood pressure to a similar degree (3.4, 4.3, and 3.1 mm Hg, respectively, versus −1.3 mm Hg for placebo) after 14 days of treatment; small changes also occurred in diastolic blood pressure (0.3, 0.8, and −0.4 mm Hg, respectively, versus −1.4 mm Hg for placebo). Changes from baseline in creatinine clearance, body weight, and urinary potassium excretion among active treatments were similar. After 28 days of treatment, findings were generally consistent with those at 14 days. No subject reported edema or discontinued treatment as the result of an adverse experience. Conclusion: In healthy elderly subjects on a sodium‐replete diet, the COX‐2 inhibitors rofecoxib and celecoxib did not differ from a nonselective nonsteroidal anti‐inflammatory drug (naproxen), in influencing renal function as measured by urinary sodium excretion, systolic and diastolic blood pressure, creatinine clearance, or weight change. Clinical Pharmacology & Therapeutics (2002) 72, 50–61; doi: 10.1067/mcp.2002.126182

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1067/mcp.2002.126182

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 161

Metadata

Authors
Schwartz, J. I., Vandormael, K., Malice, M. P., Kalyani, R. N., Lasseter, K. C., Holmes, G. B., Gertz, B. J., Gottesdiener, K. M., Laurenzi, M., Redfern, K. ‐., & Brune, K.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2002-07
Volume
72
Issue
1
Pages
50-61
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2022106950
Cited by
161
References
0
FWCI
11.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet. https://app.cochat.ai/papers/10.1067/mcp.2002.126182
The paper
Schwartz, J. I., Vandormael, K., Malice, M. P., Kalyani, R. N., Lasseter, K. C., Holmes, G. B., Gertz, B. J., Gottesdiener, K. M., Laurenzi, M., Redfern, K. ‐., & Brune, K. (2002). Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet. Clinical Pharmacology & Therapeutics. https://doi.org/10.1067/mcp.2002.126182

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.